Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

Erstveröffentlichung
2016Authors
Wendtner, Clemens M.
Hallek, Michael
Fraser, Graeme A. M.
Michallet, Anne-Sophie
Hillmen, Peter
Wissenschaftlicher Artikel
Published in
Leukemia & Lymphoma ; 57 (2016), 6. - S. 1291-1299. - ISSN 1042-8194. - eISSN 1029-2403